Jimmy Chang – Chairman & CEO, TaiMed Biologics
With over two decades of global pharmaceutical experience at Eli Lilly and Allergan, Dr Jimmy Chang returned to Taiwan to lead TaiMed Biologics, Taiwan’s first biotech to successfully commercialise a…
Address: 18201 Von Karman Ave, Suite 470. Irvine, CA 92612
Tel: (949) 769-6543
Web: http://www.taimedbiologics.com/
TaiMed Biologics was formed on September 4, 2007 to realize the vision of creating a world-class, innovation-based biotechnology company that will satisfy the unmet medical needs of patients around the world.
The company signed an agreement with Genentech for the licensing of Ibalizumab shortly after its formation. This drug candidate, also known as TMB-355, is a proprietary humanized anti-CD4 monoclonal antibody for the treatment of HIV/AIDS. A phase-2b clinical trial is currently underway and the coma expect the trial to be completed in Q1 2011.
With over two decades of global pharmaceutical experience at Eli Lilly and Allergan, Dr Jimmy Chang returned to Taiwan to lead TaiMed Biologics, Taiwan’s first biotech to successfully commercialise a…
In an effort to enhance trade and cooperation with other countries in the region and reduce dependency on mainland China, in 2016 Taiwan’s government introduced the New Southbound Policy (NSP).…
Within Taiwan’s evolving medical device sector, many innovative startups are exploring breakthrough ideas which are sparking global interest and attention – iXensor being a chief example. The company’s patented technology…
Mark Yang, CEO of GaleMed, elaborates on the medical device manufacturer’s transition from a privately-owned company to being acquired by private equity firm Nexus Point Capital. Yang goes on to…
United Biomedical, Inc. (UBI) is dedicated to the discovery, development, and commercialization of immunotherapies & vaccines for chronic and infectious diseases and is passionate about delivering science-driven innovation with platform…
James Chiu, GM of Fresenius Kabi Taiwan, discusses the affiliate’s portfolio offering of parenteral and enteral nutrition in Taiwan as well as its move towards biosimilars. In addition, Chiu highlights…
Shuhei Sekiguchi, recently-appointed managing director of Janssen Taiwan, discusses how his vast experience in marketing and sales will help him in this new role, Janssen´s market outlook for Taiwan, its…
The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each…
G-SYN Biomedical Technology is a company dedicated to resolving problems occurring from cell hypoxia. Dieter Chang, the company’s founder introduces the firm, why they decided to focus on hypoxia, their…
Philip Chen, chairman of the Taipei Exchange, discusses the capital market condition, elaborates on the significance of biotech, and shares the competitive advantages of innovation companies listing on TPEx. Chen…
Danny Liao, CEO of Taiwanese diagnostics firm Skyla discusses the reason behind splitting from parent company Lite-On, the thinking behind a move from information technology (IT) into medical diagnostics and…
The Southern Taiwan Science Park (STSP)’s Chen-Kang Su discusses how STSP has played a key role in bringing innovation to Taiwan, how collaborations between academic institutions and industry are helping…
Dr Huey-Jen Jenny Su, president of National Cheng Kung University, elaborates on her ambitions to reclaim the institution’s unique historical positioning as Taiwan’s most impactful university. She goes on to…
See our Cookie Privacy Policy Here
